Last updated: 2026-11-14 20:09:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
XORTX Therapeutics Inc. (XRTX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.09, with a market capitalization of $1.67M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.82 to $3.60. This page covers its latest market performance, valuation, price trends and company information.
$1.67M | |
$0.91 | |
$1.18 | |
$0.84 | |
$0.92 | |
1.57M | |
771.34K | |
-- | |
$3.60 | |
$0.82 | |
-- | |
-- |
XORTX Therapeutics Inc. (XRTX) last closed at $1.09 as of 2026-11-14 00:58:00, up 19.57% ($0.18) from the previous close of $0.92.
During the latest regular trading session, XRTX traded between $0.84 and $1.18, with a volume of 1.57M shares. The closing price was near the upper end and near the lower end of its 52-week range.
XRTX is up 19.57% as of the last close.
Over the past seven days, XORTX Therapeutics Inc. (XRTX) moved from $0.92 to $1.09, representing a gain of 17.93% ($0.16).
The stock traded between $0.82 and $1.20 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 336.52 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 9.7%
XRTX is currently trading at $1.09, placing it 9.7% of the way from its 52-week low of $0.82 to its 52-week high of $3.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
| Employees | 3 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to XORTX Therapeutics Inc. and XRTX stock.
Gainers InflaRx (NASDAQ:IFRX) stock rose 12.7% to $1.32 during Friday's after-market session. The market value of their outstanding shares is at $182.6 million. Instinct Bio Technical Co (NASDAQ:BIOT) stock moved
XORTX Therapeutics announced that the Japan Patent Office has issued a Decision to Grant a patent for its xanthine oxidase inhibitor compositions (XRx-101) for treating acute kidney injury and other health consequences of viral infections. The patent, expected to remain in force until March 2041, marks the company's first patent protection in Japan and strengthens its intellectual property position in one of the world's largest pharmaceutical markets.
Eligible investors can buy real shares of XORTX Therapeutics Inc. (XRTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to XRTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between XRTX shares and USD.
XRTX Shares to USD
1.00 XRTX shares = 1.085 USD
Calculations are estimates based on the latest available price and are for reference only.
